RYAM Q1 2026 Call Reinforces Challenging Turnaround Path

What happened

Rayonier Advanced Materials reported Q1 2026 results that continued the trend of weak profitability, with adjusted EBITDA under pressure from tariff headwinds and soft cellulose markets, consistent with management's earlier guidance for a step-down from 2024 levels. The company's balance sheet remains stretched, with interest coverage near zero and net debt-to-EBITDA above 3.5x, leaving no room for execution missteps. Management reiterated its strategy pivoting toward cellulose specialties and biomaterials, but we see little evidence of near-term earnings inflection, particularly given ongoing trade disputes and the structural decline in acetate tow. While the stock trades at a steep discount to a DCF estimate of $32.53, the equity is tightly coupled to balance-sheet risk and the success of a multi-year turnaround that has so far failed to generate consistent GAAP profits. The Q1 call provided no catalysts that would alter our cautious stance; we recommend monitoring for sustained free cash flow improvement and deleveraging before considering a position.

Implication

The Q1 2026 earnings call confirms the strained financial state of RYAM, with persistent GAAP losses, negligible interest coverage, and a balance sheet burdened by $794M in expensive secured debt. While the company is executing on cost cuts and biomaterials investments, the near-term outlook is dominated by tariff uncertainty, weak dissolving pulp pricing, and structural headwinds in acetate tow. We see no reason to upgrade from our WAIT stance. The equity offers potential upside only if management can deliver the ambitious >$300M EBITDA target by 2027, but the gap between ambition and track record is wide. Investors should require visible FCF growth and a clear path to net debt/EBITDA below 3x before considering meaningful exposure. The current price of around $4-6 already discounts much of the downside, but the lack of catalysts and high execution risk keep us on the sidelines.

Thesis delta

The Q1 2026 results reinforce the downward earnings trajectory and the fragility of the balance sheet. Management's turnaround plan remains unproven, and trade/tariff headwinds appear to be intensifying. Our thesis shifts slightly more bearish: the probability of a successful deleveraging by 2027 has decreased, and we see increased risk of covenant stress or equity dilution if cash flows fail to improve.